The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

Table 1 Summary of GEO cohort characteristics

	GSE17705	GSE6532-C
n	230	132
LN Positive	91 59 % DMFS at 10 years	89 70 % DMFS at 10 years
LN Negative	139 85 % DMFS at 10 years	43 75 % DMFS at 10 years
Age	NR	61
Age Range	NR	40–88
Distant Metastasis at 10 years (n)	62	33
Overall 10 year DMFS	58.7 %	71.1 %
Location	MD Anderson, US	Guy’s Hosptial, UK, John Radcliffe Hospital, UK & Uppsala University Hospital, Sweden
Submission Group	Hatzis, Nuvera Biosciences, Woburn Mass	Loi et al., Institut Jules Bordet, Belgium
Affymetrix Chip	U133.A	U133.A & U133.2

ISSN: 1471-2407